AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor ...

The biomedical company announced plans on Monday to bring 1,200 jobs and relocate 300 jobs from Charlotte to Rock Hill.

NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd.

AbCellera has announced the appointment of Victor Sandor, M.D. C.M, to its Board of Directors as an independent director.

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one ...

The shape of that competition is given physical form at the 2026 BIO International Convention (BIO 2026) in San Diego, ...

Now, Quantum BioPharma Ltd. is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly ...

Bionyra is emerging with three licensed assets aimed at diseases with high unmet need despite currently available treatments, including atopic dermatitis and inflammatory bowel disease. (iStock / ...

The takeover represents the latest push by Biogen into immunology, expanding beyond its traditional stronghold in neurology medicines. The company is fresh off a $5.6 billion purchase of Apellis ...

Vedana’s lealdership team, from left: Dr. Rob Lenz, board chair; Leon Garcia, co-founder and chief scientific officer; Anurag Agarwal, co-founder and CEO; and Dr. Ernesto Aycardi, chief medical ...

Prostate cancer can be treated with targeted therapies, but there are still opportunities to improve on this approach. MultiValent Biotherapies is going after two validated cancer targets with a ...

LOS ALTOS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a ...